Technosphere® Insulin technology

Diabetes Technology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2007, Pages

  Richardson, Peter C ^a   Boss, Anders H ^a,b  

^a MannKind Corporation   (United States)

^b MannKind Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; DRY POWDER; DYSPNEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MICROENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POWDER INHALER; PRIORITY JOURNAL; ARTICLE; BLOOD; DRUG EFFECT; EQUIPMENT DESIGN; GLUCOSE CLAMP TECHNIQUE; INHALATIONAL DRUG ADMINISTRATION; KINETICS; METABOLISM; NEBULIZER;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EQUIPMENT DESIGN; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; NEBULIZERS AND VAPORIZERS;

EID: 34250736274     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0212     Document Type: Conference Paper

References (26)

1. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-1239.
2. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-229.
3. Luzio SD, Owens DR, Vora J, Dolben J, Smith H: Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/ hyperinsulinaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Res 1991;16:63-67.
4. 1c. Diabetes Care 2003;26:881-885.
5. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931.
6. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625.
7. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
8. Guerci B, Sauvanet JP: Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 2005;31(Suppl):4S7-4S24.
9. Gin H, Hanaire-Broutin H: Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005;31:7-13.
10. Hirsch IB: Insulin analogues. N Engl J Med 2005;352:174-183.
11. Heinemann L: Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682.
12. Cefalu WT: Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 2001;33:579-586.
13. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, Martinez L, Ross S, Bolinder B, Stridde E: Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427-128.
14. Pfützner A, Forst T: Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005;2:1097-1106.
15. Bergeron RJ, Phanstiel O IV, Yao GW, Milstein S, Weimar WR: Macromolecular self-assembly of diketopiperazine tetrapeptides. J Am Chem Soc 1994;116:8479-8484.
16. Bergeron RJ, Yao GW, Erdos GW, Milstein S, Gao F, Weimar WR, Phanstiel O IV: An investigation of the impact of molecular geometry upon microcapsule self-assembly. J Am Chem Soc 1995;117:6658-6665.
17. nd ed. New York: Informa Healthcare USA, 2007 (in press).
18. Boss AH, Rave K, Heise T, Cheatham WW, Pfützner A: Insulin bio-effect is limited by speed of absorption and elimination: similarities between an inhaled insulin formulation that mimics first-phase kinetics and i.v. insulin [abstract 872]. Diabetologia 2004;47:A314.
19. Rave KM, Heise T, Pfützner A, Steiner S, Heinemann L: Results of a dose-response study with a new pulmonary insulin formulation and inhaler [abstract 305-PP]. Diabetes 2000;49(Suppl 1):A75.
20. Boss AH, Heise T, Rave K, Cheatham WW: The variability and time-action profile of inhaled Technosphere Insulin compares favorably to that of subcutaneous human regular insulin [abstract 358-OR]. Diabetes 2005;54(Suppl 1):A88.
21. Boss AH, Rave K, Cheatham WW, Heise T: Inhaled Technosphere Insulin: glucose elimination at the right time? [abstract 443-P]. Diabetes 2005;54(Suppl 1):A109.
22. Novolin R [package insert]. Princeton, NJ: Novo Nordisk, 2005.
23. Pfützner A, Mann AE, Steiner SS: Technosphere Insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;4:589-594.
24. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA: Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 1996;97:2351-2361.
25. th Annual Scientific Sessions of the American Diabetes Association, June 10-14, 2005, San Diego, CA.
26. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K: Technosphere Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21.